HU229319B1 - Cathartic composition - Google Patents

Cathartic composition Download PDF

Info

Publication number
HU229319B1
HU229319B1 HU0302422A HUP0302422A HU229319B1 HU 229319 B1 HU229319 B1 HU 229319B1 HU 0302422 A HU0302422 A HU 0302422A HU P0302422 A HUP0302422 A HU P0302422A HU 229319 B1 HU229319 B1 HU 229319B1
Authority
HU
Hungary
Prior art keywords
pond
lake
diarrhea
compound
taken
Prior art date
Application number
HU0302422A
Other languages
English (en)
Hungarian (hu)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU229319(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of HUP0302422A2 publication Critical patent/HUP0302422A2/hu
Publication of HUP0302422A3 publication Critical patent/HUP0302422A3/hu
Publication of HU229319B1 publication Critical patent/HU229319B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
HU0302422A 2000-09-05 2001-09-04 Cathartic composition HU229319B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition
PCT/JP2001/007628 WO2002020007A1 (en) 2000-09-05 2001-09-04 Cathartic composition

Publications (3)

Publication Number Publication Date
HUP0302422A2 HUP0302422A2 (hu) 2003-10-28
HUP0302422A3 HUP0302422A3 (en) 2005-02-28
HU229319B1 true HU229319B1 (en) 2013-10-28

Family

ID=24630250

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302422A HU229319B1 (en) 2000-09-05 2001-09-04 Cathartic composition

Country Status (25)

Country Link
US (7) US6414016B1 (enExample)
EP (2) EP1315485B1 (enExample)
JP (3) JP2004508327A (enExample)
KR (2) KR100918223B1 (enExample)
CN (1) CN100335049C (enExample)
AR (2) AR030609A1 (enExample)
AT (1) ATE476975T1 (enExample)
AU (2) AU2001282615B2 (enExample)
BR (1) BRPI0114042B8 (enExample)
CA (1) CA2419741C (enExample)
CZ (1) CZ304740B6 (enExample)
DE (2) DE60131547T2 (enExample)
DK (2) DK1315485T3 (enExample)
ES (2) ES2347697T3 (enExample)
HU (1) HU229319B1 (enExample)
IL (2) IL154534A0 (enExample)
MX (1) MXPA03001959A (enExample)
NL (1) NL300757I1 (enExample)
NO (1) NO332701B1 (enExample)
NZ (1) NZ524401A (enExample)
PT (2) PT1315485E (enExample)
RU (1) RU2694361C3 (enExample)
TW (1) TWI305147B (enExample)
WO (1) WO2002020007A1 (enExample)
ZA (1) ZA200301673B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
WO2004037268A1 (en) * 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
JP4889219B2 (ja) * 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
US8337891B2 (en) 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
CN101048163A (zh) * 2004-09-02 2007-10-03 苏坎波公司 用于治疗胃肠道疾病的前列腺素衍生物
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CA2595898C (en) * 2005-01-27 2015-04-28 Sucampo Ag Method and composition for treating central nervous system disorders
DK1853271T3 (da) 2005-03-04 2011-01-24 Sucampo Ag Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5711442B2 (ja) * 2005-04-12 2015-04-30 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用
KR20140147142A (ko) 2006-01-24 2014-12-29 가부시키가이샤 아루떼꾸 우에노 바이-사이클릭 화합물을 함유하는 약학적 조성물 및 바이-사이클릭 화합물의 안정화 방법
JP4851467B2 (ja) * 2006-02-07 2012-01-11 株式会社アールテック・ウエノ プロスタグランジン誘導体の製造法
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
US8372425B2 (en) * 2008-10-31 2013-02-12 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament
CA2748607A1 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2750487A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
BR112012006069A8 (pt) * 2009-09-18 2017-10-10 Adolor Corp Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
WO2011054087A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
WO2011072383A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
WO2011091513A1 (en) 2010-01-28 2011-08-04 Apotex Pharmachem Inc. Polymorphic forms of lubiprostone
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
ES2735992T3 (es) 2013-04-12 2019-12-23 Ardelyx Inc Compuestos de unión a NHE3 y procedimientos para inhibir el transporte de fosfatos
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
AR105029A1 (es) * 2015-06-19 2017-08-30 Sucampo Ag Composición farmacéutica que comprende derivado de ácido graso
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CN110494721B (zh) * 2017-04-20 2022-06-24 株式会社岛津制作所 分光光度计
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (enExample) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
EP0310305B1 (en) 1987-10-02 1992-07-22 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Cathartics
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
DK1062952T3 (da) * 1998-03-11 2003-11-24 Grelan Pharmaceutical Co Brusende enteropræparater
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
ATE308606T1 (de) * 2000-07-14 2005-11-15 Henkel Kgaa Kompartiment-hohlkörper enthaltend wasch-, reinigungs- oder spülmittelportion
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
PT1857105E (pt) 2010-10-08
JP2004508327A (ja) 2004-03-18
HUP0302422A2 (hu) 2003-10-28
WO2002020007A1 (en) 2002-03-14
ES2347697T3 (es) 2010-11-03
DE60131547D1 (de) 2008-01-03
RU2694361C3 (ru) 2020-07-20
ZA200301673B (en) 2003-11-26
RU2694361C9 (ru) 2019-12-25
CN100335049C (zh) 2007-09-05
US6414016B1 (en) 2002-07-02
US20140235665A1 (en) 2014-08-21
US20030040528A1 (en) 2003-02-27
KR100901102B1 (ko) 2009-06-08
NO20030996L (no) 2003-05-02
AR100291A2 (es) 2016-09-28
CA2419741A1 (en) 2002-03-14
US20120022152A1 (en) 2012-01-26
DE60142810D1 (de) 2010-09-23
CN1655776A (zh) 2005-08-17
EP1315485A1 (en) 2003-06-04
US20050222195A1 (en) 2005-10-06
US6610732B2 (en) 2003-08-26
AU8261501A (en) 2002-03-22
NL300757I2 (enExample) 2015-12-29
BR0114042A (pt) 2003-07-22
DE60131547T2 (de) 2008-10-23
JP2009286806A (ja) 2009-12-10
BRPI0114042B1 (pt) 2016-11-08
CZ304740B6 (cs) 2014-09-17
ES2296786T3 (es) 2008-05-01
HUP0302422A3 (en) 2005-02-28
EP1857105A2 (en) 2007-11-21
DK1315485T3 (da) 2008-03-03
AR030609A1 (es) 2003-08-27
DK1857105T3 (da) 2010-09-20
JP2009114217A (ja) 2009-05-28
CA2419741C (en) 2010-11-30
TWI305147B (en) 2009-01-11
NO20030996D0 (no) 2003-03-04
US20120237598A1 (en) 2012-09-20
JP4684334B2 (ja) 2011-05-18
KR20080091278A (ko) 2008-10-09
US8114890B1 (en) 2012-02-14
US8071613B2 (en) 2011-12-06
BRPI0114042B8 (pt) 2021-05-25
NO332701B1 (no) 2012-12-10
AU2001282615B2 (en) 2006-06-22
KR100918223B1 (ko) 2009-09-21
RU2694361C2 (ru) 2019-07-12
IL154534A0 (en) 2003-09-17
NL300757I1 (enExample) 2015-12-29
EP1315485B1 (en) 2007-11-21
US20030216465A1 (en) 2003-11-20
US8748454B2 (en) 2014-06-10
PT1315485E (pt) 2008-01-23
IL154534A (en) 2010-04-29
EP1857105A3 (en) 2008-03-05
KR20030029919A (ko) 2003-04-16
EP1857105B1 (en) 2010-08-11
NZ524401A (en) 2004-08-27
ATE476975T1 (de) 2010-08-15
MXPA03001959A (es) 2003-06-24

Similar Documents

Publication Publication Date Title
HU229319B1 (en) Cathartic composition
ES2938560T3 (es) Formulaciones de cannabinoides estables
DE69611369T2 (de) Sublingual oder bukkal verabreichte arzneistoffe mit gesteuerter freisetzung
DE69927805T2 (de) Neue fettanaloge zur behandlung von sekundärer restenose
ES2261523T3 (es) Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria.
PT1158959E (pt) Composições e métodos para a administração melhorada de agentes terapêuticos hidrófobos
BRPI0614484A2 (pt) extrato de scf contendo glicose cardìaca
LU87560A1 (fr) Composition pharmaceutique intraveineuse et procede pour sa preparation
HUE027395T2 (hu) Eszközök nyálkahártyán keresztül történõ bejuttatására, javított felszívódással
KR20080092373A (ko) 치료용 조성물
US20170258917A1 (en) Solubility of therapeutic agents
EP0306422A1 (fr) Nouvelles formes galéniques de béta-2-mimétiques pour administration par voie per- et sublinguale
JP2017532354A (ja) 注射用ブプレノルフィン製剤
DE69835824T2 (de) Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
DE68903814T2 (de) Etoposid-loesungen.
CN102631405A (zh) 一种复方芹菜素纳米乳抗高血压药物
US20090062382A1 (en) External preparation for improving coital function
DD267187A5 (de) Verfahren zur herstellung von mitteln zur bekaempfung des asthma bronchiale und der chonisch obstruktiven bronchitis
AU1565492A (en) Dry starch-iodine pharmaceutical formulations
DE69529819T2 (de) Neue kombination eines betablockers mit einem lokalanästhetikum
US5910318A (en) Treatment of iodine deficiency diseases
HU217431B (hu) Ipriflavont tartalmazó gyógyászati készítmények, és eljárás ezek előállítására
JP4493018B2 (ja) 平滑筋蠕動抑制剤
RU2065307C1 (ru) Способ лечения первичного рака печени и набор для лечения первичного рака печени
EA006776B1 (ru) Фармацевтическая композиция для лечения диабетической невропатии